PLASMA PCSK9 AND CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES

被引：0
|
作者：
El Khoury, Petra [1 ,2 ]
Roussel, Ronan [3 ,4 ,5 ]
Fumeron, Frederic [4 ,5 ]
Velho, Gilberto [5 ]
Jacob, Marie-Paule [1 ,4 ]
Steg, Gabriel [1 ,4 ,6 ,7 ]
Potier, L. [3 ,4 ,5 ]
Ghaleb, Youmna [1 ,2 ,4 ]
Elbitar, Sandy [1 ,2 ,4 ]
Abifadel, Marianne [1 ,2 ]
Boileau, Catherine [1 ,4 ,8 ]
Marre, Michel [3 ,4 ,5 ]
Varret, Mathilde [1 ,4 ]
Hansel, Boris [3 ,4 ,5 ]
机构：
[1] INSERM, U1148, Paris, France
[2] St Joseph Univ, Beruth, Lebanon
[3] CHU Bichat, Aphp, Dept Nutr, Paris, France
[4] Denis Diderot Univ Paris 7, Paris, France
[5] INSERM, U1138, Paris, France
[6] CHU Bichat, Aphp, Dept Cardiol, Paris, France
[7] Imperial Coll, NHLI, Royal Brompton Hosp, London, England
[8] CHU Bichat, Aphp, Dept Genet, Paris, France
来源：
ATHEROSCLEROSIS | 2017年 / 263卷
关键词：
D O I：
10.1016/j.atherosclerosis.2017.06.263
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAG142
引用
收藏
页码：E81 / E81
页数：1
相关论文
共 50 条
  • [1] Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
    El Khoury, Petra
    Roussel, Ronan
    Fumeron, Frederic
    Abou-Khalil, Yara
    Velho, Gilberto
    Mohammedi, Kamel
    Jacob, Marie-Paule
    Steg, Philippe Gabriel
    Potier, Louis
    Ghaleb, Youmna
    Elbitar, Sandy
    Ragot, Stephanie
    Andreata, Francesco
    Caligiuri, Giusepinna
    Hadjadj, Samy
    Boileau, Catherine
    Marre, Michel
    Abifadel, Marianne
    Varret, Mathilde
    Hansel, Boris
    DIABETES OBESITY & METABOLISM, 2018, 20 (04): : 943 - 953
  • [2] PCSK9 Inhibitors and Cardiovascular Events
    Goemann, Iuri M.
    Londero, Thiza M.
    Dora, Jose M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 773 - 774
  • [3] PCSK9 inhibition and type 2 diabetes
    Lotta, Luca A.
    Griffin, Simon J.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (12): : 926 - 927
  • [4] PCSK9 Inhibitors and Cardiovascular Events Reply
    Sabatine, Marc S.
    Wasserman, Scott M.
    Stein, Evan A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 774 - 775
  • [5] PCSK9 Inhibition to Reduce Cardiovascular Events
    Dullaart, Robin P. F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (18): : 1790 - 1791
  • [6] ASSOCIATION OF APOLIPOPROTEINS PLASMA LEVELS WITH PCSK9 IN TYPE 2 DIABETES MELLITUS
    Baudin, Bruno
    Nekaies, Ymene
    Baudin, Bruno
    Kelbousi, Sami
    Sakly, Mohsen
    Attia, Nebil
    ATHEROSCLEROSIS, 2017, 263 : E273 - E274
  • [7] Do PCSK9 inhibitors reduce cardiovascular events?
    Kolber, Michael R.
    Nickonchuk, Tony
    Turgeon, Ricky
    CANADIAN FAMILY PHYSICIAN, 2018, 64 (09) : 669 - 669
  • [8] Liraglutide decreases plasma PCSK9 in patients with type 2 diabetes not treated with statins
    Verges, B.
    Hassid, J.
    Rouland, A.
    Bouillet, B.
    Baillot-Rudoni, S.
    Petit, J. -M.
    Duvillard, L.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 210 - 210
  • [9] Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins
    Verges, Bruno
    Hassid, Jonathan
    Rouland, Alexia
    Bouillet, Benjamin
    Simoneau, Isabelle
    Petit, Jean-Michel
    Duvillard, Laurence
    DIABETES & METABOLISM, 2022, 48 (02)
  • [10] Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression
    Shapiro, Michael D.
    Tavori, Hagai
    Oleaga, Carlota
    Miles, Joshua
    Fazio, Sergio
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
12345